Publications: 143 in 2026-03. -1.5% share of all MeSH-indexed PubMed records vs the same month last year (148 in 2025-03).
PublicationsPubMed
1432026-03
-1.5% share of all MeSH-indexed PubMed records vs same month last year (148 in 2025-03)provisional · settling
0.13% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 2 in 2026-08. No percentage shown. No percentage shown: both months are under 15 records. The count is ranked in its own history instead. Clinical trials: latest count 2 is in the 21st percentile, running low, versus 320 months since 2000.
Clinical trialsClinicalTrials.gov
22026-08
21st percentilerunning low, versus 320 months since 2000low volume
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 97 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 97 is in the 97th percentile, near its historical high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
972026-08
97th percentilenear its historical high, versus 15-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 78 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 78 is in the 50th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
782026-08
50th percentilein its typical range, versus 15-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 15 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 15 is in the 47th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
152026-08
47th percentilein its typical range, versus 15-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 143 is in the 66th percentile, in its typical range, versus 320 months since 2000.
66thpercentile
in its typical range
143/mo · higher than 65% of 320 months since 2000
Clinical trials
Clinical trials: latest count 2 is in the 21st percentile, running low, versus 320 months since 2000.
21stpercentile
running low
2/mo · higher than 18% of 320 months since 2000
NIH grantsprovisional
NIH grants: latest count 97 is in the 97th percentile, near its historical high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
97thpercentile
near its historical high
97/mo · higher than 93% of 15-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 78 is in the 50th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
50thpercentile
in its typical range
78/mo · higher than 47% of 15-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 15 is in the 47th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
47thpercentile
in its typical range
15/mo · higher than 40% of 15-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 15 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 320 mo; NIH grants 2025 to 2026 · 15 mo; Patents 2025 to 2026 · 15 mo; Preprints 2025 to 2026 · 15 mo.
Publications2000 to 2026 · 320 mopeak 286/mo
Clinical trials2000 to 2026 · 320 mopeak 24/mo
NIH grants2025 to 2026 · 15 mobackfill pendingpeak 97/mo
Patents2025 to 2026 · 15 mobackfill pendingpeak 117/mo
Preprints2025 to 2026 · 15 mobackfill pendingpeak 20/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-07..2026-06
4%of works have an industry affiliation
Inserm219
University of North Carolina at Chapel Hill174
University of Washington155
University of Colorado Denver137
Cystic Fibrosis Foundation123
Clinical trials
Lead sponsors · 2023-09..2026-08
0%industry-led in 2026-08
Vertex Pharmaceuticals IncorporatedIndustry10
Hospices Civils de LyonAcademic/other7
Assiut UniversityAcademic/other6
Hacettepe UniversityAcademic/other4
Indiana UniversityAcademic/other4
NIH grants
Funded institutions · 2025-06..2026-08
622awards in window
UNIVERSITY OF IOWAIA · $18.2M · P30/R0135
UNIV OF NORTH CAROLINA CHAPEL HILLNC · $17.7M · P30/R0132
EMORY UNIVERSITYGA · $13.5M · R01/P3030
DARTMOUTH COLLEGENH · $13.8M · P30/R0126
CINCINNATI CHILDRENS HOSP MED CTROH · $13.3M · P30/R0124
Would you read a monthly digest for Cystic Fibrosis?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Cystic Fibrosis. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Cystic Fibrosis.
How we map "Cystic Fibrosis"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Cystic Fibrosis"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10